Attovia Therapeutics, a clinical-stage biopharmaceutical company, completed an upsized IPO by selling 19.55 million shares, including an underwriter option, raising approximately $332.40 million. The stock opened at $21.00 per share on Nasdaq and reached a 52-week high of $22.05 during its first trading day. The company focuses on developing treatments for immune system diseases using its proprietary ATTOBODY biologics platform. This successful IPO provides Attovia with significant capital to advance its drug development programs.
Arhaus reported record Q2 net revenue of $385 million, a 7.4% increase year-over-year, driven by strong customer demand and a 12.5% rise in comparable sales. Earnings per share of $0.28 beat estimates by 75%, supported by a 16.1% increase in gross ma...
Flutter Entertainment's stock dropped 13% following a significant earnings miss and the announcement of CEO Peter Jackson's departure. The company reported Q2 earnings of $0.49 per share, well below the expected $0.60, and cut its full-year U.S. prof...
Aflac reported Q2 2026 earnings per share of $1.75, slightly below analyst estimates, while revenue of $4.12 billion narrowly exceeded projections. The company's improved profitability in Japan, highlighted by a better benefit-to-premium ratio of 61....
YXT.COM Group Holding Limited's stock plunged 66.07% following a registered direct offering that raised concerns about share dilution. The leveraged ETF Tradr 2X Long APP Daily ETF (APPX) fell 39.22%, highlighting the risks of leveraged products. Des...
Sanuwave Health reported Q2 2026 revenue of $9.7 million, down 3% from $10.1 million in Q2 2025, with a net loss of $0.7 million compared to net income last year. The company faced challenges from CMS reimbursement changes and a secondary market for ...
